This volume, which includes contributions from leading scientists and clinicians in the field, provides definitive, state-of-the-art information on STAT inhibitors in a biological and clinical context. It gives an overview of the biology of the STAT family of transcription factors and their role in cancer etiology. Additionally, it describes the raft of therapeutic approaches being used to inhibit STATs in the context of various cancers, covering the full spectrum of therapeutic approaches to inhibiting STATs, and presenting emerging data from clinical trials.
|
1 STATs in Health and Disease |
|
|
1 | (32) |
|
|
|
|
|
|
|
2 STAT Proteins in Cancer |
|
|
33 | (16) |
|
|
|
|
|
3 Translating STAT Inhibitors from the Lab to the Clinic |
|
|
49 | (20) |
|
|
|
|
|
4 Historical Development of STAT3 Inhibitors and Early Results in Clinical Trials |
|
|
69 | (26) |
|
|
|
|
|
|
|
5 STAT3 Inhibitors in Cancer: A Comprehensive Update |
|
|
95 | (68) |
|
|
|
|
|
|
|
6 Targeting Upstream Janus Kinases |
|
|
163 | (14) |
|
|
|
|
|
7 Inhibitors of Upstream Inducers of STAT Activation |
|
|
177 | (14) |
|
|
| Index |
|
191 | |
Alister C. Ward is Foundation Professor/Director of Pre-Clinical Studies, School of Medicine, Deakin University, Geelong, Australia.
